Drugs / 17ß-estradiol
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00420342 | Jan 2007 → Sep 2008 | hypertensive disorder | Bayer | Completed | Missed primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT01656434 | Nov 2012 → Feb 2014 | — | Organon and Co | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00651599 | Jul 2004 → May 2005 | vasomotor rhinitis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00102141 | Apr 2004 → Jul 2005 | essential hypertension | Bayer | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00145522 | Nov 2005 → Mar 2009 | — | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT00537836 Comparator | Oct 2007 → Dec 2008 | vasomotor rhinitis | Bayer | Completed | No outcome recorded |
| — | NCT04100655 Background | Oct 2019 → Jun 2020 | uterine disorder | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| — | NCT01418209 Comparator | Nov 2011 → Jan 2013 | — | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 17-ß estradiol | “NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.” NCT01656434 ↗ |
| Route | Oral | “given as tablets orally” NCT00102141 ↗ |